GUD Insider Trading

Insider Ownership Percentage: 46.36%
Insider Buying (Last 12 Months): C$2,024,822.60
Insider Selling (Last 12 Months): C$1,162,837.50

Knight Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Knight Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Knight Therapeutics Share Price & Price History

Current Price: C$5.50
Price Change: Price Decrease of -0.2 (-3.51%)
As of 06/17/2024 05:20 PM ET

This chart shows the closing price history over time for GUD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Knight Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2024Amal KhouriSenior OfficerSell20,000C$5.80C$116,022.00
6/5/2024Jonathan Ross GoodmanDirectorBuy5,000C$5.80C$29,000.00
5/29/2024Robert Nathaniel LandeDirectorSell15,000C$5.91C$88,600.50
5/23/2024Robert Nathaniel LandeDirectorSell20,000C$5.94C$118,710.00
5/7/2024Sime ArmoyanInsiderSell15,000C$5.95C$89,250.00
4/11/2024Sime ArmoyanInsiderSell10,900C$5.95C$64,855.00
4/1/2024Sime ArmoyanInsiderBuy6,200C$5.25C$32,550.00
3/25/2024Sime ArmoyanInsiderBuy351,000C$5.25C$1,842,750.00
1/22/2024Sime ArmoyanInsiderSell28,200C$5.75C$162,150.00
1/19/2024Sime ArmoyanInsiderSell91,000C$5.75C$523,250.00
10/23/2023Sime ArmoyanInsiderBuy1,100C$4.35C$4,785.00
9/15/2023Sime ArmoyanInsiderBuy26,400C$4.38C$115,737.60
8/11/2022Sime ArmoyanInsiderSell65,500C$5.80C$380,103.0511,404,478
7/29/2022Sime ArmoyanInsiderSell100,000C$5.80C$580,110.0011,504,478
6/20/2022Samira SakhiaDirectorBuy19,455C$5.14C$99,998.70158,954
6/16/2022Long Zone Holdings Inc. InsiderBuy18,000C$5.18C$93,240.0021,723,933
5/18/2022Long Zone Holdings Inc. InsiderBuy20,000C$5.17C$103,400.0021,705,933
5/18/2022Samira SakhiaDirectorBuy19,305C$5.18C$99,999.90136,734
4/13/2022Janice Jean MurrayDirectorBuy1,900C$5.30C$10,070.006,115
12/23/2021Jonathan Ross GoodmanDirectorBuy3,600C$5.24C$18,864.00765,059
12/13/2021Samira SakhiaDirectorBuy15,800C$5.20C$82,160.0083,786
12/3/2021Jonathan Ross GoodmanDirectorBuy19,200C$5.21C$100,032.00
11/22/2021Jonathan Ross GoodmanDirectorBuy800C$5.23C$4,184.00672,984
11/22/2021Long Zone Holdings Inc. InsiderBuy18,000C$5.29C$95,220.0021,685,133
11/19/2021Robert Nathaniel LandeDirectorBuy15,000C$5.39C$80,850.00260,614
11/19/2021Robert Nathaniel LandeDirectorBuy15,000C$5.39C$80,850.00260,614
11/15/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.25C$94,500.00654,184
9/20/2021Arvind UtchanahSenior OfficerBuy600C$5.20C$3,120.009,913
8/23/2021Jonathan Ross GoodmanDirectorBuy4,300C$5.36C$23,048.00631,788
8/18/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.39C$97,020.00609,488
7/14/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.30C$95,400.00591,488
7/2/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.24C$94,320.00555,488
1/13/2021Robert Nathaniel LandeDirectorBuy17,000C$5.27C$89,590.0072,714
9/15/2020Robert Nathaniel LandeDirectorBuy414C$6.04C$2,500.5646,128
See Full Table

SEC Filings (Institutional Ownership Changes) for Knight Therapeutics (TSE:GUD)

13.68% of Knight Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Knight Therapeutics logo
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More on Knight Therapeutics

Today's Range

Now: C$5.50
Low: C$5.48
High: C$5.71

50 Day Range

MA: C$5.87
Low: C$5.54
High: C$6.15

52 Week Range

Now: C$5.50
Low: C$4.35
High: C$6.22

Volume

109,084 shs

Average Volume

70,087 shs

Market Capitalization

C$557.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Who are the company insiders with the largest holdings of Knight Therapeutics?

Knight Therapeutics' top insider shareholders include:
  1. Sime Armoyan (Insider)
  2. Samira Sakhia (Director)
  3. Amal Khouri (Senior Officer)
  4. Jonathan Ross Goodman (Director)
  5. Robert Nathaniel Lande (Director)
Learn More about top insider investors at Knight Therapeutics.